Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMB-05X in Tenosynovial Giant Cell Tumor
NCT05349643Phase 2Completed
- Sponsor
- AmMax Bio
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of ABM-05X in tenosynovial giant cell tumor (TGCT), sponsored by AmMax Bio. Started Jan 2023; status: completed.
02
Drugs
ABM-05X
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT05349643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349643.